AbbVie Inc. (ABBV) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $6.43B; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $3.99B; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $1.90B; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $4.89B; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $6.43B | (m) | (m) | (m) | $322.00M* | $3.44B* | $4.29B | (m) | $3.63B | $662.00M |
| 2026-03-31 | Reported | (m) | $3.99B | (m) | (m) | (m) | $265.00M | $3.83B | $4.22B | (m) | $3.58B | $342.00M |
| 2025-09-30 | Reported | (m) | $1.90B | (m) | (m) | (m) | $381.00M* | $7.02B* | $5.30B | (m) | $3.57B | $526.00M |
| 2025-06-30 | Reported | (m) | $4.89B | (m) | (m) | (m) | $269.00M* | $5.15B* | $4.35B | (m) | $3.25B | $613.00M |
| 2025-03-31 | Reported | (m) | $3.73B | (m) | (m) | (m) | $235.00M | $1.64B | $4.00B | (m) | $3.29B | $372.00M |
| 2024-09-30 | Reported | (m) | $3.83B | (m) | (m) | (m) | $249.00M* | $5.45B* | $4.21B | (m) | $4.21B | $520.00M |
| 2024-06-30 | Reported | (m) | $4.00B | (m) | (m) | (m) | $241.00M* | $2.27B* | $4.20B | (m) | $3.38B | $773.00M |
| 2024-03-31 | Reported | (m) | $2.80B | (m) | (m) | (m) | $193.00M | $4.04B | $4.09B | (m) | $3.31B | $383.00M |
| 2023-09-30 | Reported | (m) | $2.28B | (m) | (m) | (m) | $219.00M* | $7.57B* | $6.49B | (m) | $3.37B | $172.00M |
| 2023-06-30 | Reported | (m) | $4.51B | (m) | (m) | (m) | $178.00M* | $6.32B* | $4.24B | (m) | $3.27B | $583.00M |
| 2023-03-31 | Reported | (m) | $2.77B | (m) | (m) | (m) | $175.00M | $4.19B | $3.99B | (m) | $3.04B | $234.00M |
| 2022-09-30 | Reported | (m) | $4.60B | (m) | (m) | (m) | $177.00M* | $7.60B* | $5.02B | (m) | $3.30B | $448.00M |
| 2022-06-30 | Reported | (m) | $3.29B | (m) | (m) | (m) | $143.00M* | $5.00B* | $4.17B | (m) | $5.41B | $255.00M |
| 2022-03-31 | Reported | (m) | $4.72B | (m) | (m) | (m) | $162.00M | $4.91B | $4.05B | (m) | $3.13B | $436.00M |
| 2021-09-30 | Reported | (m) | $4.31B | (m) | (m) | (m) | $217.00M* | $7.93B* | $4.39B | (m) | $3.08B | $508.00M |
| 2021-06-30 | Reported | (m) | $4.44B | (m) | (m) | (m) | $195.00M* | $4.89B* | $4.52B | (m) | $3.16B | $394.00M |
| 2021-03-31 | Reported | (m) | $4.10B | (m) | (m) | (m) | $188.00M | $4.88B | $4.21B | (m) | $2.84B | $312.00M |
| 2020-09-30 | Reported | (m) | $3.25B | (m) | (m) | (m) | $217.00M* | $5.83B* | $5.05B | (m) | $2.85B | $187.00M |
| 2020-06-30 | Reported | (m) | $752.00M | (m) | (m) | (m) | $177.00M* | $3.09B* | $3.71B | (m) | $3.53B | $46.00M |
| 2020-03-31 | Reported | (m) | $3.60B | (m) | (m) | (m) | $125.00M | $3.81B | $1.94B | (m) | $1.70B | $88.00M |
| 2019-09-30 | Reported | (m) | $2.62B | (m) | (m) | (m) | $154.00M* | $4.55B* | $1.92B | (m) | $1.66B | $117.00M |
| 2019-06-30 | Reported | (m) | $3.40B | (m) | (m) | (m) | $128.00M* | $2.48B* | $1.82B | (m) | $1.65B | $66.00M |
| 2019-03-31 | Reported | (m) | $3.01B | (m) | (m) | (m) | $107.00M | $3.02B | $1.69B | (m) | $1.68B | $88.00M |
| 2018-09-30 | Reported | (m) | $3.16B | (m) | $8.24B | (m) | $282.00M* | $4.52B* | $1.83B | (m) | $1.92B | $14.00M |
| 2018-06-30 | Reported | (m) | $2.76B | (m) | $8.28B | (m) | $114.00M* | $2.87B* | $1.93B | (m) | $1.76B | $29.00M |
| 2018-03-31 | Reported | (m) | $2.90B | (m) | $7.93B | (m) | $119.00M | $2.65B | $1.93B | (m) | $1.79B | $14.00M |
| 2017-09-30 | Reported | (m) | $2.69B | (m) | $7.00B | (m) | $126.00M* | $3.27B* | $1.62B | (m) | $1.46B | $464.00M |
| 2017-06-30 | Reported | (m) | $2.66B | (m) | $6.94B | (m) | $126.00M* | $2.00B* | (m) | (m) | $1.51B | $438.00M |
| 2017-03-31 | Reported | (m) | $2.41B | (m) | $6.54B | (m) | $95.00M | $2.10B | (m) | (m) | $1.37B | $375.00M |
| 2016-09-30 | Reported | (m) | $2.36B | (m) | (m) | (m) | $113.00M* | $1.45B* | (m) | (m) | $1.38B | $416.00M |
| 2016-06-30 | Reported | (m) | $2.39B | (m) | (m) | (m) | $131.00M* | $1.92B* | (m) | (m) | $1.47B | $486.00M |
| 2016-03-31 | Reported | (m) | $2.28B | (m) | (m) | (m) | $121.00M | $2.13B | (m) | (m) | $1.35B | $422.00M |
| 2015-09-30 | Reported | (m) | $1.89B | (m) | (m) | (m) | $127.00M* | (m) | (m) | (m) | $1.47B | $408.00M |
| 2015-06-30 | Reported | (m) | $1.85B | (m) | (m) | (m) | $115.00M* | (m) | (m) | (m) | $1.70B | $312.00M |
| 2015-03-31 | Reported | (m) | $1.69B | (m) | (m) | (m) | $145.00M | (m) | (m) | (m) | $1.47B | $374.00M |
| 2014-09-30 | Reported | (m) | $960.00M | (m) | (m) | (m) | $180.00M* | (m) | (m) | (m) | $1.59B | $181.00M |
| 2014-06-30 | Reported | (m) | $1.51B | (m) | (m) | (m) | $142.00M* | (m) | (m) | (m) | $1.45B | $335.00M |
| 2014-03-31 | Reported | (m) | $1.35B | (m) | (m) | (m) | $137.00M | (m) | (m) | (m) | $1.34B | $306.00M |
| 2013-09-30 | Reported | (m) | $1.37B | (m) | (m) | (m) | $133.00M* | (m) | (m) | (m) | $1.26B | $322.00M |
| 2013-06-30 | Reported | (m) | $1.45B | (m) | (m) | (m) | $119.00M* | (m) | (m) | (m) | $1.41B | $300.00M |
| 2013-03-31 | Reported | (m) | $1.30B | (m) | (m) | (m) | $88.00M | (m) | (m) | (m) | $1.24B | $271.00M |
| 2012-09-30 | Reported | (m) | $1.60B | (m) | (m) | (m) | -$18.00M* | (m) | (m) | (m) | $1.08B | $19.00M |
| 2012-06-30 | Reported | (m) | $1.42B | (m) | (m) | (m) | $94.00M* | (m) | (m) | (m) | $1.25B | $135.00M |
| 2012-03-31 | Reported | (m) | $978.00M | (m) | (m) | (m) | $162.00M | (m) | (m) | (m) | $1.25B | $123.00M |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | $15.07B | (m) | $61.16B | (m) | $1.21B | $19.03B | $18.20B | (m) | $14.01B | $2.36B |
| 2024-12-31 | Reported | (m) | $9.14B | (m) | $56.33B | (m) | $974.00M | $18.81B | $16.90B | (m) | $14.75B | -$570.00M |
| 2023-12-31 | Reported | (m) | $12.76B | (m) | $54.32B | (m) | $777.00M | $22.84B | $20.41B | (m) | $12.87B | $1.38B |
| 2022-12-31 | Reported | (m) | $18.12B | (m) | $58.05B | (m) | $695.00M | $24.94B | $17.41B | (m) | $15.26B | $1.63B |
| 2021-12-31 | Reported | (m) | $17.92B | (m) | $56.20B | (m) | $787.00M | $22.78B | $17.45B | (m) | $12.35B | $1.44B |
| 2020-12-31 | Reported | (m) | $11.36B | (m) | $45.80B | (m) | $798.00M | $17.59B | $15.39B | (m) | $11.30B | -$1.22B |
| 2019-12-31 | Reported | (m) | $12.98B | (m) | $33.27B | (m) | $552.00M | $13.32B | $7.44B | (m) | $6.94B | $544.00M |
| 2018-12-31 | Reported | (m) | $6.38B | (m) | $32.75B | (m) | $638.00M | $13.43B | $7.72B | (m) | $7.40B | -$490.00M |
| 2017-12-31 | Reported | (m) | $9.54B | (m) | $28.22B | (m) | $529.00M | $9.96B | $7.04B | (m) | $6.29B | $2.42B |
| 2016-12-31 | Reported | (m) | $9.34B | (m) | $25.64B | (m) | $479.00M | (m) | $5.83B | (m) | $5.88B | $1.93B |
| 2015-12-31 | Reported | (m) | $7.54B | (m) | (m) | (m) | $532.00M | (m) | (m) | (m) | $6.39B | $1.50B |
| 2014-12-31 | Reported | (m) | $3.41B | (m) | (m) | (m) | $612.00M | (m) | (m) | (m) | $7.72B | $595.00M |
| 2013-12-31 | Reported | (m) | $5.66B | (m) | (m) | (m) | $491.00M | (m) | (m) | (m) | $5.35B | $1.20B |
| 2012-12-31 | Reported | (m) | $5.82B | (m) | (m) | (m) | $333.00M | (m) | (m) | (m) | $4.99B | $450.00M |
| 2011-12-31 | Reported | (m) | $3.62B | (m) | (m) | (m) | $356.00M | (m) | (m) | (m) | $5.89B | $235.00M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |